Ann: Zelira Meets Primary Endpoints for Insomnia Trial, page-139

Have been thinking about this a lot also. I wonder if the market is waiting for the full results before committing. It's possible the interim Ann is a bit confusing and hasn't provided enough detail / confidence in the results. For example, people seem to be uncertain about the use of ISI and while the trial demonstrated statistical significance, it's not entirely clear how the patients responded in terms of their actual sleeping behaviours or general well-being.

I expect / hope these questions will be thoroughly answered in the full update end of March and the market will respond accordingly. Personally I'm far more confident in this company today than I was last week, just need the SP to reflect it. Just a bit longer to wait imo...